Polyporus umbellatus inhibited tumor cell proliferation and promoted tumor cell apoptosis by down-regulating AKT in breast cancer

Biomedicine and Pharmacotherapy

Volumn 83, Issue , 2016, Pages 526-535

  Tan, Xiao Lang ^a   Guo, Lei ^b   Wang, Gui Hua ^a  

^a CHANGSHA CENTRAL HOSPITAL   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

AKT; Apoptosis; Breast cancer; Polyporus umbellatus; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; PLANT EXTRACT; POLYPORUS UMBELLATUS EXTRACT; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MCF 7 CELL LINE; MIGRATION INHIBITION; MOUSE; NONHUMAN; POLYPORUS UMBELLATUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; POLYPORUS;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PLANT EXTRACTS; POLYPORUS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978636757     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.06.049     Document Type: Article

References (39)

1. [1] Sánchez-Muñoz, A., Ribelles, N., Alba, E., Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?. Clin. Transl. Oncol. 12 (2010), 614–620.
2. [2] Mouridsen, H.T., Robert, N.J., The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur. J. Cancer 41 (2005), 1678–1689.
3. [3] Grau, J.J., Zanon, G., Caso, C., Gonzalez, X., Rodriguez, A., Caballero, M., Biete, A., Prognosis in women with breast cancer and private extra insurance coverage. Ann. Surg. Oncol. 20 (2013), 2822–2827.
4. [4] Mereno-Aspitia, A., Hillman, D.W., Dyar, S.H., Tenner, K.S., Gralow, J., Kaufman, P.A., et al. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cacner receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trail N9831. Cancer 119 (2013), 2675–2682.
5. [5] Wolff, A.C., Hammond, M.E., Hicks, D.G., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. J. Clin. Oncol. 31 (2013), 3997–4013.
6. [6] Reiner, A.S., John, E.M., Brooks, J.D., Lynch, C.F., Bernstein, L., Mellemkjær, L., et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. J. Clin. Oncol. 31 (2013), 433–439.
7. [7] Nahleh, Z.A., Srikantiah, R., Safa, M., et al. Male breast cancer in the veterans affairs population: a comparative analysis. Cancer 109 (2007), 1471–1477.
8. [8](a) Lizarraga, I.M., Sugg, S.L., Weigel, R.J., Scott-Conner, C.E., Review of risk factors for the development of contralateral breast cancer. Am. J. Surg. 206 (2013), 704–708.
9. [8](b) Tang, J.M., He, Q.Y., Guo, R.X., Chang, X.J., Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51 (2006), 181–191.
10. [9] Chapuis, N., Tamburini, J., Cornillet-Lefebvre, P., et al. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 95 (2010), 415–423.
11. [10] Muders, M.H., Zhang, H., Wang, E., Tindall, D.J., Datta, K., Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer Res. 69 (2009), 6042–6048.
12. [11] Opel, D., Poremba, C., Simon, T., Debatin, K.M., Fulda, S., Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res. 67 (2007), 735–745.
13. [12] Gottlieb, T.M., Martinez-Leal, J.F., Seger, R., Taya, Y., Oren, M., Cross-talk between Akt, p53 and MDM2: possible implications for the regulation of apoptosis. Oncogene 21 (2002), 1299–1303.
14. [13] Mayo, L.D., Donner, D.B., The PTEN, MDM2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci. 27 (2002), 462–467.
15. [14] Horn, H., Vousden, K., Coping with stress: multiple ways to activate p53. Oncogene 26 (2007), 1306–1316.
16. [15] Yu, F., Deng, H., Yao, H., Liu, Q., Su, F., Song, E., Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 29 (2010), 4194–4204.
17. [16] Cheng, G.Z., Park, S., Shu, S., He, L., Kong, W., Zhang, W., Yuan, Z., Wang, L.H., Cheng, J.Q., Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr. Cancer Drug Targets 8 (2008), 2–6.
18. [17] Li, L., Wang, Q., Si C: the effects of zhuling-duotang, hepatitis B vaccine and bacillus Calmette-Guerin on immunoactivities of peripheral blood mononuclear cells: an in vitro research. Zhonghua Nei Ke Za Zhi 34 (1995), 392–395.
19. [18] Xing, Y.M., Chen, J., Song, C., Liu, Y.Y., Guo, S.X., Wang, C.L., Nox gene expression and cytochemical localization of hydrogen peroxide in Polyporus umbellatus sclerotial formation. Int. J. Mol. Sci. 14 (2013), 22967–22981.
20. [19] Kim, T.H., Kim, J.S., Kim, Z.H., Huang, R.B., Chae, Y.L., Wang, R.S., Khz-cp (crude polysaccharide extract obtained from the fusion of Ganoderma lucidum and Polyporusumbellatus mycelia) induces apoptosis by increasing intracellular calcium levels and activating P38 and NADPH oxidase-dependent generation of reactive oxygen species in SNU-1 cells. BMC Compl. Altern. Med., 14, 2014, 236.
21. [20] Zhang, G.W., Qin, G.F., Han, B., Li, C.X., Yang, H.G., Nie, P.H., Zeng, X., Efficacy of Zhuling polyporus polysaccharide with BCG to inhibit bladder carcinoma. Carbohydr. Polym. 118 (2015), 30–35.
22. [21] Xing, Y.M., Yin, W.Q., Liu, M.M., Wang, C.L., Guo, S.X., Oxalic acid and sclerotial differentiation of Polyporus umbellatus. Sci. Rep., 5, 2015, 10759.
23. [22] Zhao, Y.Y., Traditional uses, phytochemistry, pharmacology, pharmacokinetics and quality control of Polyporusumbellatus (Pers.) Fries: a review. J. Ethnopharmacol. 149 (2013), 35–48.
24. [23] Suzuki, K., Matsubara, H., Recent advances in p53 research and cancer treatment. J. Biomed. Biol., 2011, 9783122011.
25. [24] Bourougaa, K., Naski, N., Boularan, C., et al. Endoplasmic reticulum stress induces G2 cell-cycle arrest via mRNA translation of the p53 isoform p53/47. Mol. Cell 38 (2010), 78–88.
26. [25] Perisanidis, C., Perisanidis, B., Wrba, F., et al. Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J. Oral. Pathol. Med. 41 (2012), 40–46.
27. [26] Horn, H., Vousden, K., Coping with stress: multiple ways to activate p53. Oncogene 26 (2007), 1306–1316.
28. [27] Hershman, D.L., Kushi, L.H., Shao, T., et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J. Clin. Oncol. 28 (2010), 4120–4128.
29. [28] Courtney, K.D., Corcoran, R.B., Engelman, J.A., The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28 (2010), 1075–1083.
30. [29] Fresno Vara, J.A., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., González-Barón, M., PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30 (2004), 193–204.
31. [30] Chen, H., Xie, L., Liu, B., Clinical significance of MDM2 as a tumor biomarker. Chin.-Ger. J. Clin. Oncol. 11 (2012), 356–360.
32. [31] Olsson, H., Hultman, P., Rosell, J., Söderkvist, P., Jahnson, S., MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1. BMC Urol., 13, 2016, 52013.
33. [32] Ma, H.B., Huang, T., Han, F., Chen, W.Y., Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk—a meta-analysis. Asian Pac. J. Cancer Prev. 13 (2012), 2841–2846.
34. [33] Jiang, L., Wang, C., Lei, F., Zhang, L., Zhang, X., Liu, A., Wu, G., Zhu, J., Song, L., miR-93 promotes cell proliferation in gliomas through activation of PI3K/Akt signaling pathway. Oncotarget 6 (2015), 8286–8299.
35. [34] Cheng, G.Z., Park, S., Shu, S., He, L., Kong, W., Zhang, W., Yuan, Z., Wang, L.H., Cheng, J.Q., Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr. Cancer Drug Targets 8 (2008), 2–6.
36. [35] Balogova, L., Maslanakova, M., Dzurova, L., Miskovsky, P., Stroffekova, K., Bcl-2 proapoptotic proteins distribution in U-87 MG glioma cells before and after hypericin photodynamic action. Gen. Physiol. Biophys. 32 (2013), 179–187.
37. [36] Levine, B., Sinha, S., Kroemer, G., Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 4 (2008), 600–606.
38. [37] Hojabrpour, P., Waissbluth, I., Ghaffari, M., Cox, M.E., Duronio, V., CaMKII-gamma mediates phosphorylation of BAD at Ser170 to regulate cytokine-dependent survival and proliferation. Biochem. J. 442 (2012), 139–149.
39. [38] Stauffer, S.R., Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737. Curr. Top. Med. Chem. 7 (2007), 961–965.